Clinical trial
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two…
NCT00116779 · Ferring Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00116779 |
|---|---|
| Title | A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer |
| Official title | An Open-label, Randomized, Multi-center, Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer Dosed for Thirteen 28-day Cycles |
| Lead sponsor | Ferring Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Degarelix |
| Enrollment | 127 |
| Start date | Feb 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | Jul 1, 2005 |
| Last update posted | Dec 19, 2011 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: